| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Veterans Administration Medical Center and University of California, San Francisco, CA 94121; and
University of California Comprehensive Cancer Center, San Francisco, CA 94143
By homology to triggering receptor expressed by myeloid cells-2, we screened the mouse expressed sequence tag database and isolated a new single Ig domain receptor, which we have expressed and characterized. The receptor is most similar in sequence to the human CMRF-35 receptor, and thus we have named it CMRF-35-like molecule (CLM)-1. By screening the mouse genome, we determined that CLM-1 was part of a multigene family located on a small segment of mouse chromosome 11. Each contains a single Ig domain, and they are expressed mainly in cells of the myeloid lineage. CLM-1 contains multiple cytoplasmic tyrosine residues, including two that lie in consensus immunoreceptor tyrosine-based inhibitory motifs, and we demonstrate that CLM-1 can associate with Src-homology 2 containing phosphatase-1. Expression of CLM-1 mRNA is down-regulated by treatment with receptor activator of NF-
B ligand (RANKL), a cytokine that drives osteoclast formation. Furthermore, expression of CLM-1 in the osteoclastogenic cell line RAW (RAW.CLM-1) prevents osteoclastogenesis induced by RANKL and TGF-
. RAW.CLM-1 cells fail to multinucleate and do not up-regulate calcitonin receptor, but they express tartrate-resistant acid phosphatase, cathepsin K, and 3 integrin, suggesting that osteoclastogenesis is blocked at a late-intermediate stage. Thus, we define a new family of myeloid receptors, and demonstrate that the first member of this family, CLM-1, is an inhibitory receptor, able to block osteoclastogenesis.
This article has been cited by other articles:
|
|
 |
|
  Y. Mori, S. Tsuji, M. Inui, Y. Sakamoto, S. Endo, Y. Ito, S. Fujimura, T. Koga, A. Nakamura, H. Takayanagi, et al. Inhibitory Immunoglobulin-Like Receptors LILRB and PIR-B Negatively Regulate Osteoclast Development J. Immunol., October 1, 2008; 181(7): 4742 - 4751. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Yamanishi, J. Kitaura, K. Izawa, T. Matsuoka, T. Oki, Y. Lu, F. Shibata, S. Yamazaki, H. Kumagai, H. Nakajima, et al. Analysis of mouse LMIR5/CLM-7 as an activating receptor: differential regulation of LMIR5/CLM-7 in mouse versus human cells Blood, January 15, 2008; 111(2): 688 - 698. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Can, S. Tahara-Hanaoka, K. Hitomi, T. Nakano, C. Nakahashi-Oda, N. Kurita, S.-i. Honda, K. Shibuya, and A. Shibuya Caspase-Independent Cell Death by CD300LF (MAIR-V), an Inhibitory Immunoglobulin-Like Receptor on Myeloid Cells J. Immunol., January 1, 2008; 180(1): 207 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Izawa, J. Kitaura, Y. Yamanishi, T. Matsuoka, T. Oki, F. Shibata, H. Kumagai, H. Nakajima, M. Maeda-Yamamoto, J. P. Hauchins, et al. Functional Analysis of Activating Receptor LMIR4 as a Counterpart of Inhibitory Receptor LMIR3 J. Biol. Chem., June 22, 2007; 282(25): 17997 - 18008. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Nakahashi, S. Tahara-Hanaoka, N. Totsuka, Y. Okoshi, T. Takai, N. Ohkohchi, S.-i. Honda, K. Shibuya, and A. Shibuya Dual Assemblies of an Activating Immune Receptor, MAIR-II, with ITAM-Bearing Adapters DAP12 and FcR{gamma} Chain on Peritoneal Macrophages J. Immunol., January 15, 2007; 178(2): 765 - 770. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Alvarez-Errico, J. Sayos, and M. Lopez-Botet The IREM-1 (CD300f) Inhibitory Receptor Associates with the p85{alpha} Subunit of Phosphoinositide 3-Kinase J. Immunol., January 15, 2007; 178(2): 808 - 816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Shi, K. Luo, D. Xia, T. Chen, G. Chen, Y. Jiang, N. Li, and X. Cao DIgR2, dendritic cell-derived immunoglobulin receptor 2, is one representative of a family of IgSF inhibitory receptors and mediates negative regulation of dendritic cell-initiated antigen-specific T-cell responses Blood, October 15, 2006; 108(8): 2678 - 2686. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Fujimoto, H. Takatsu, and H. Ohno CMRF-35-like molecule-5 constitutes novel paired receptors, with CMRF-35-like molecule-1, to transduce activation signal upon association with FcR{gamma} Int. Immunol., October 1, 2006; 18(10): 1499 - 1508. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Martinez-Barriocanal and J. Sayos Molecular and Functional Characterization of CD300b, a New Activating Immunoglobulin Receptor Able to Transduce Signals through Two Different Pathways. J. Immunol., September 1, 2006; 177(5): 2819 - 2830. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Umemoto, T. Tanaka, H. Kanda, S. Jin, K. Tohya, K. Otani, T. Matsutani, M. Matsumoto, Y. Ebisuno, M. H. Jang, et al. Nepmucin, a novel HEV sialomucin, mediates L-selectin-dependent lymphocyte rolling and promotes lymphocyte adhesion under flow J. Exp. Med., June 12, 2006; 203(6): 1603 - 1614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Guinzberg, D. Cortes, A. Diaz-Cruz, H. Riveros-Rosas, R. Villalobos-Molina, and E. Pina Inosine released after hypoxia activates hepatic glucose liberation through A3 adenosine receptors Am J Physiol Endocrinol Metab, May 1, 2006; 290(5): E940 - E951. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Bachelet, A. Munitz, A. Moretta, L. Moretta, and F. Levi-Schaffer The Inhibitory Receptor IRp60 (CD300a) Is Expressed and Functional on Human Mast Cells J. Immunol., December 15, 2005; 175(12): 7989 - 7995. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Aguilar, D. Alvarez-Errico, A. C. Garcia-Montero, A. Orfao, J. Sayos, and M. Lopez-Botet Molecular Characterization of a Novel Immune Receptor Restricted to the Monocytic Lineage J. Immunol., December 1, 2004; 173(11): 6703 - 6711. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
